Results 101 to 110 of about 43,474 (209)

Targeting CAR to the Peptide-MHC Complex Reveals Distinct Signaling Compared to That of TCR in a Jurkat T Cell Model. [PDF]

Cancers (Basel), 2021
Wu L, Brzostek J, Sankaran S, Wei Q, Yap J, Tan TYY, Lai J, MacAry PA, Gascoigne NRJ.   +8 more
europepmc   +1 more source

sGC stimulator BAY 41‐8543 improves survival and ventricular function in a rat model of doxorubicin‐induced cardiomyopathy with nephrotic syndrome

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anthracyclines such as doxorubicin (DOXO) remain a cornerstone of cancer therapy but are associated with a high risk of cardiotoxicity and subsequent heart failure (HF). Impairment of NO/soluble guanylyl cyclase (sGC)/cGMP pathway has been reported in anthracycline‐induced cardiomyopathy.
Olga Gawrys, Petra Škaroupková, Soňa Kikerlová, Zdeňka Vaňourková, Martina Hüttl, Olga Lenčová, Kasin Yadunandam Anandam, Svenja Stomberg, Sönke Behrends, Barbara Szeiffová Bačová, Matúš Sykora, Lisa Dietz, Peter Sandner, Luděk Červenka, Martin Štěrba   +14 more
wiley   +1 more source

CAGE-seq reveals that HIV-1 latent infection does not trigger unique cellular responses in a Jurkat T cell model. [PDF]

J Virol, 2021
Matsui H, Shirakawa K, Konishi Y, Hirabayashi S, Sarca AD, Fukuda H, Nomura R, Stanford E, Horisawa Y, Kazuma Y, Matsumoto T, Yamazaki H, Murakawa Y, Battivelli E, Verdin E, Koyanagi Y, Takaori-Kondo A.   +16 more
europepmc   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

BTK Inhibitor Ibrutinib Reduces Bispecific Antibody‐Related CRS Without Undermining the Anti‐Tumor Efficacy

Cancer Science, EarlyView.
BTK inhibition reprograms macrophages to suppress IL‐6/IL‐8/IL‐10‐driven CRS without compromising BsAb efficacy. ABSTRACT Bispecific antibodies (BsAbs) have shown marked efficacy in relapsed or refractory (R/R) B‐cell non‐Hodgkin lymphoma (B‐NHL). However, their clinical utility is constrained by cytokine release syndrome (CRS).
Jiaowu Cao, Dingyao Hu, Jie Lv, Jin Chai, Yue Wang, Jie Chen, Xiaoqiang Yan, Jun Zhu, Hui Yu   +8 more
wiley   +1 more source

Contribution of endosomal proteins EHD1 and EHD4 to the HIV‐1 replication cycle

The FEBS Journal, EarlyView.
EHD1 and EHD4, two key trafficking proteins, regulate multiple stages of HIV‐1 infection: In producer cells, they help produce fully infectious virus particles, regulate Envelope protein incorporation in a cell‐type‐dependent manner, and limit the accumulation of antiviral IFITM proteins in virions.
Grégory Pacini, Konstantinos Poalas, Margaux Versapuech, Clarisse Berlioz‐Torrent, Katy Janvier   +4 more
wiley   +1 more source

A guide to transcriptional cyclin‐dependent kinases in cancer

The FEBS Journal, EarlyView.
Transcriptional cyclin‐dependent‐kinases (tCDKs) facilitate gene expression by promoting RNA polymerase II (RNAPII) progression through discrete phases of the transcription cycle. Aberrant tCDK activity is detectable in different human cancers, thereby contributing to de‐regulated gene expression programs that drive oncogenic phenotypes.
Jennifer R. Devlin, Salla Kyheröinen, Ricky W. Johnstone   +2 more
wiley   +1 more source

Structural Optimization of Carboxy-Terminal Phenylalanine-Modified Dendrimers for T-Cell Association and Model Drug Loading

Pharmaceutics
Dendrimers are potent nanocarriers in drug delivery systems because their structure can be precisely controlled. We previously reported that polyamidoamine (PAMAM) dendrimers that were modified with 1,2-cyclohexanedicarboxylic acid (CHex) and ...
Hiroya Shiba, Tomoka Hirose, Akinobu Sakai, Ikuhiko Nakase, Akikazu Matsumoto, Chie Kojima   +5 more
doaj   +1 more source

Combining TAG‐72CAR with anti‐MUC16CAR improves the potency of ovarian cancer treatment

The FEBS Journal, EarlyView.
Tz‐KBBCAR, a combinatorial CAR targeting MUC16 and TAG‐72, enhances the precision of ovarian cancer immunotherapy. By requiring both tumour antigens for full activation, Tz‐KBBCAR was designed to eliminate MUC16+/TAG‐72+ cancer cells, while sparing MUC16+/TAG‐72‐ healthy cells.
Alicia Villatoro, Aurore Dougé, Klara Krpina, Lea‐Marie Schmitz, Christopher Forcados, Fatemeh Kaveh, Andrea Estrella Arias‐Díaz, Pascal Gelebart, Emmet McCormack, Renata Stripecke, Miguel Abal, Ben Davidson, Else Marit Inderberg, Sébastien Wälchli   +13 more
wiley   +1 more source

TIM‐3 Functions as an Activator of NK Cells in GBM and Can Be Upregulated by Torin‐1: Implications for Exogenous NK Cell Transplantation

Immunology, EarlyView.
Unlike generalized mTOR inhibitors, Torin‐1 uniquely drives compensatory upregulation of TIM‐3 on human NK cells, shielding them from immunosuppression while concurrently inhibiting glioblastoma (GBM) growth. Selecting or preconditioning ex vivo NK cell products for high TIM‐3 expression can offer a combination strategy for adoptive cell therapy in GBM.
Yuning Liu, Tram Dao, Shambhavi Borde, Diana Dinh, Sofia Lombardi, Sandra Torregrosa‐Allen, Haley A. Harper, Veronika Slivova, Aaron Cohen‐Gadol, MacKenzie McIntosh, Bennet D. Elzey, Sandro Matosevic   +11 more
wiley   +1 more source